Integra LifeSciences (NASDAQ:IART) Updates FY 2024 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its FY 2024 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of 2.410-2.490 for the period, compared to the consensus estimate of 2.450. The company issued revenue guidance of $1.6 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion. Integra LifeSciences also updated its Q4 guidance to $0.81-0.89 EPS.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on IART. BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th. Bank of America reduced their price target on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research report on Monday, October 7th. Morgan Stanley boosted their price target on Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a report on Monday, July 15th. Truist Financial cut their target price on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a report on Monday, October 14th. Finally, Citigroup boosted their target price on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research note on Tuesday. Three research analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company. According to MarketBeat.com, Integra LifeSciences has a consensus rating of “Hold” and an average target price of $27.25.

Integra LifeSciences Trading Up 3.3 %

Shares of IART stock opened at $24.91 on Wednesday. Integra LifeSciences has a 1-year low of $16.81 and a 1-year high of $45.42. The company has a market cap of $1.93 billion, a price-to-earnings ratio of 85.90, a PEG ratio of 0.66 and a beta of 1.08. The company has a debt-to-equity ratio of 1.17, a current ratio of 3.39 and a quick ratio of 2.10. The stock has a 50 day simple moving average of $18.68 and a 200-day simple moving average of $24.41.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.02. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The company had revenue of $380.80 million during the quarter, compared to analysts’ expectations of $375.81 million. During the same period in the prior year, the business posted $0.76 earnings per share. The firm’s revenue for the quarter was down .4% on a year-over-year basis. On average, equities research analysts expect that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.